What is Zacks Research’s Forecast for LEXX Q2 Earnings?

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Investment analysts at Zacks Research issued their Q2 2026 earnings per share (EPS) estimates for Lexaria Bioscience in a note issued to investors on Tuesday, February 10th. Zacks Research analyst J. Vandermosten expects that the company will post earnings per share of ($0.07) for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share. Zacks Research also issued estimates for Lexaria Bioscience’s Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.26) EPS and FY2027 earnings at ($0.31) EPS.

Lexaria Bioscience (NASDAQ:LEXX) last released its quarterly earnings data on Tuesday, January 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.14 million. Lexaria Bioscience had a negative return on equity of 226.58% and a negative net margin of 1,685.84%.

Several other research firms also recently issued reports on LEXX. Wall Street Zen downgraded shares of Lexaria Bioscience from a “hold” rating to a “sell” rating in a research note on Sunday, December 7th. HC Wainwright decreased their price objective on Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating for the company in a report on Friday, December 26th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lexaria Bioscience in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Lexaria Bioscience has an average rating of “Hold” and an average target price of $1.50.

Lexaria Bioscience Price Performance

LEXX opened at $0.62 on Thursday. Lexaria Bioscience has a fifty-two week low of $0.46 and a fifty-two week high of $1.90. The firm has a market capitalization of $15.49 million, a price-to-earnings ratio of -1.11 and a beta of 0.56. The company’s 50 day moving average price is $0.76 and its two-hundred day moving average price is $0.91.

Institutional Trading of Lexaria Bioscience

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in Lexaria Bioscience by 25.7% during the 4th quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock worth $136,000 after acquiring an additional 44,939 shares during the period. Byrne Asset Management LLC boosted its position in shares of Lexaria Bioscience by 236.8% during the 4th quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock valued at $65,000 after purchasing an additional 74,180 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Lexaria Bioscience during the third quarter worth approximately $28,000. Institutional investors own 13.06% of the company’s stock.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.